Check out $CPRX. Catalyst Pharmaceuticals Announces Encouraging Top-Line Results in Proof-of-Concept Trial of Vigabatrin in Patients With Treatment-Refractory Tourette's Disorder CORAL GABLES, Fla., June 24, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced top-line results in an open-label, proof-of-concept trial of CPP-109 (vigabatrin) used to treat patients suffering from Tourette's Disorder (TD) that were refractory to all other previous treatments. One of four patients demonstrated a very clear, clinically significant reduction in tics, and two others showed about a 25% reduction in tics, but without subjective clinical improvement.
Patrick J. McEnany, Catalyst's Chief Executive Officer, stated, “We see these data as promising despite the small number of subjects, single center, open-label design trial." Mr. McEnany went on to say, "These top-line results demonstrate an encouraging signal of activity in adult treatment-refractory patients with Tourette’s Disorder. We believe that CPP-109’s mechanism of action validates the potential for CPP-115 to be a candidate for the treatment of Tourette's Disorder. We are evaluating our options and will be meeting with the Co-Principal Investigators of the trial, as well as other key opinion leaders, to determine the next steps in development.”
This proof-of-concept trial of CPP-109 (Vigabatrin) for Treatment-Refractory Tourette's Disorder was conducted by Barbara Coffey M.D., M.S., Co-Principal Investigator and Chief of the Tics and Tourette’s Clinical and Research Program at the Icahn School of Medicine at Mount Sinai in New York, in collaboration with Dr. Jonathan D. Brodie at the NYU Langone Medical Center, the Co-Principal Investigator and lead inventor of this use of GABA-AT inhibitors. The trial was designed to obtain preliminary data regarding clinical effect, dosage, and tolerability of vigabatrin in subjects at least 18 years of age with a DSM-IV-TR diagnosis of Tourette's Disorder, who exhibited unsatisfactory response to all prior treatments.
Dr. Coffey said, “The clinical signal from this small open label trial, despite its limitations, is encouraging and warrants further investigation. The only formally approved medications to treat Tourette’s Disorder are first generation antipsychotic drugs which block D2 dopamine receptors; however, they are infrequently used in clinical practice because of their severe and unacceptable side effects.” Dr. Coffey continued, “Of particular note is that these patients were refractory to all previous treatments; one of the subjects has elected to continue treatment, and has remained on vigabatrin for two years. Drugs in the GABA-aminotransferase inhibitor class may offer new hope to treatment-refractory TD patients who have no other acceptable options.” Dr. Brodie added, "The positive long term response generated by even a single refractory patient opens the possibility that appropriately monitored GABA-AT inhibitors may offer an additional clinical alternative in the care of younger patients who may require longer term treatment."
The 8-week clinical trial was designed as an open label trial to evaluate the potential effect of GABA-aminotransferase inhibition as a mechanism for reducing tics in patients with treatment-refractory Tourette’s Disorder. Vigabatrin was used as a "research surrogate" to demonstrate the utility of GABA-aminotransferase (GABA-AT) blockade, with the expectation that upon successfully demonstrating the utility of this mechanism, further development activities would focus on the potentially safer, more potent GABA-AT inhibitor, CPP-115.
During the trial, each subject's Yale Global Tic Severity Score (YGTSS), Clinical Global impression for Tics (CGI-Tics: the doctor's assessment of motor and vocal tic symptom severity), and Global Assessment of Functioning score (GAF: an assessment of psychological, social, and occupational impairment) were collected at baseline (prior to treatment) and at various points during treatment. There was a statistically significant change between baseline and week six of treatment (the last point at which subjects were on the maximum dose) for all the tic assessments, and a clinically significant change for all of the assessments in one of the four subjects. This subject was featured as a treatment success on Mount Sinai Hospital's Patient Stories for the Tics and Tourette's Program web page. Two other subjects also showed a measurable change in tic assessments, but without subjective improvement. Visual field testing was conducted before and after treatment, and no significant alterations to vision were detected. One of the subjects has remained on vigabatrin for two years, and periodic visual field testing has shown no alteration in the subject's field of vision.
In recent years, GABA-ergic drugs have become an active and promising area of research to identify potential Tourette’s Disorder treatments. Recent research at the University of Nottingham in the United Kingdom suggests that increased GABA in the supplementary motor area of the brain down-regulates tics associated with Tourette's Disorder. GABA-AT inhibitors, like vigabatrin and its potentially safer, more potent analog, CPP-115, would increase GABA, effectively increasing the gain of this down-regulating pathway.
About Tourette's Disorder
Tourette’s Disorder (TD) occurs in all ethnic groups; males are affected three to four times more often than females. The Centers for Disease Control and Prevention (CDC) reported in 2009 TD prevalence estimates from a national, telephone-based survey in which they asked parents if their children had received a diagnosis of the disorder. The trial found that three of every 1,000 children have TD, but it is thought that this underestimates the true occurrence of the disorder. The prevalence of TD in adults is expected to be significantly less than in children as tic symptoms generally abate in later adolescence or early adulthood.
Tourette's Disorder (TD) is a neurodevelopmental disorder characterized by multiple tics, which are repetitive, non-rhythmic involuntary movements and vocalizations that persist for more than one year. Onset occurs in most children by about age five to six years. Some of the more common simple motor tics include eye blinking, facial grimacing, shoulder shrugging, and head or neck jerking. Common simple vocal tics, include grunting, throat clearing, coughing and squeaking. Among the most dramatic and disabling complex tics are those that result in self-harm, such as punching or poking oneself, or complex vocal tics such as coprolalia (uttering swear words) or echolalia (repeating the words or phrases of others). Many patients with TD experience additional neurobehavioral problems including inattention, hyperactivity and impulsivity, and obsessive-compulsive symptoms such as intrusive thoughts/worries and repetitive rituals.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette’s Disorder. Catalyst's lead candidate, Firdapse® for the treatment of LEMS, recently completed testing in a global, multi-center, pivotal Phase 3 trial resulting in positive top-line data. Firdapse® for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and orphan drug designation for CMS. Firdapse® is the first and only European approved drug for symptomatic treatment in adults with LEMS.
Catalyst is also developing CPP-115 to treat infantile spasms, epilepsy and other neurological conditions associated with reduced GABA-ergic signaling, like post-traumatic stress disorder and Tourette’s Disorder. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including whether the receipt of breakthrough therapy designation for Firdapse® will expedite the development and review of Firdapse® by the FDA or the likelihood that the product will be found to be safe and effective, what clinical trials and studies will be required before Catalyst can submit an NDA for Firdapse® for the treatment of CMS and whether any such required clinical trials and studies will be successful, whether an NDA for Firdapse® will ever be accepted for filing by the FDA, the timing of any such NDA filing or acceptance, whether Catalyst will be the first company to receive approval for amifampridine (3,4-DAP), giving it 7-year marketing exclusivity for its product, whether CPP-115 will be determined to be safe for humans, whether CPP-115 will be determined to be effective for the treatment of infantile spasm, post-traumatic stress disorder, Tourette’s Disorder or any other indications, whether any of Catalyst's product candidates will ever be approved for commercialization or successfully commercialized, and those other factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2014 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date. Contact:
Investor Contact Brian Korb The Trout Group LLC (646) 378-2923 bkorb@troutgroup.com
Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 529-2522 pmcenany@catalystpharma.com
Media Contacts David Schull Matt Middleman, M.D. Russo Partners (212) 845-4271 (212) 845-4272 david.schull@russopartnersllc.com matt.middleman@russopartnersllc.com
? View Comments (0) Recommended for You
Play Greek crisis: Tsipras says 'no deal' with creditors
The Greek prime minister said his government's proposed reforms have not been accepted by its creditors, according to a statement. CNBC55 mins ago Lightning Round: Too late to get in on Netflix?
Jim Cramer gives his take at rapid speed for caller favorite stocks of the day. CNBC NFLX $681.19 0.93% Cancer Therapy Boosts Appeal of Juno, Kite as Targets: Real M&A
Juno Therapeutics Inc., Kite Pharma Inc., Bluebird Bio Inc. and Cellectis SA are among firms working on CAR T, a gene therapy that supercharges the immune system. “Big pharma companies such as Pfizer, Merck, Roche and AstraZeneca are closely watching the firms developing CAR T and getting ready to… Bloomberg Philippine Casino's Bet on China Sours
In February 2014, Melco Crown Entertainment Ltd. co-Chairman James Packer described the construction of the City of Dreams casino in Manila as a “bet on China.” Sixteen months on, the gamble hasn’t paid off. With a government crackdown on corruption in China scaring customers away from Macau, where… Bloomberg Why Vladimir Putin Wants Texas to Secede from the U.S.
References to Texas have become strangely common in statements of Russian officials, up to and including President Vladimir Putin who, as Michel notes, accused the U.S. of “grabbing” Texas from Mexico in a rambling speech to the nation last December. The Fiscal Times To-Do List for New Boeing CEO: Weighing Sikorsky Bid, 747’s Fate
Boeing Co.’s Dennis Muilenburg becomes chief executive officer next week with a to-do list of decisions that could reshape the world’s largest planemaker. As Jim McNerney retires after a decade as CEO, the 51-year-old Muilenburg moves up from chief operating officer to lead a company bent on… Bloomberg Kraft Declares Regular & Special Dividend for Heinz Merger - Analyst Blog
Kraft Foods Group, Inc.'s (KRFT) board of directors recently announced a regular quarterly dividend of 55 cents per share, payable on Jul 31 to shareholders of record as on Jul 27. Zacks KFT $41.10 0.11% Is Fiat Chrysler Staging a Takeover Plan for GM?
June 23 -- Following General Motors’ spurning of a merger offer from Fiat Chrysler, there’s talk of plans for a possible hostile takeover attempt by Fiat Chrysler. Bloomberg’s David Welch reports on “Market Makers.” Bloomberg Video GM $36.30 0.30% Play Netflix splits stock 7 for 1
With the long-anticipated move, the soaring stock will start trading at its post-split price next month. CNBC Should Kinder Morgan Bid for Williams Companies?
Despite rejecting a $48 billion takeover bid this week, pipeline specialist Williams Cos. left the door open for a deal by retaining advisors to review strategic alternatives. Among these options are ... Investopedia WMB $58.94 -3.15% DuPont: After the Split, a Chemours Dividend Cut?
In a note dated Jun 22, Credit Suisse analysts John McNulty and Matthew Freedman worry that Chemours (CC.W) will be forced to cut its dividend once it's spun off from DuPont (DD). Prior to the IPO, DuPont committed Chemours to pay a $100M quarterly dividend in order for the combined entity to pay… Barrons.com CS $28.05 0.04% 8 Funds That Investors Are Fleeing in Droves
Should you hold on or bail? Morningstar The CEO of Morgan Stanley does something super type-A before bed every night
Morgan Stanley CEO James Gorman is very particular. The 56-year-old Australia native is big on... Business Insider MS $40.21 0.90% Play Cramer's Mad Dash: AT&T upgraded
Jim Cramer explains why shares of AT&T are poised to move higher and Ambarella is a hot stock. CNBC Videos Oil Prices Surge Ahead of U.S. Inventory Data
Oil prices reversed course today, surging to their highest point in nearly a week amid a rebound in oil products ahead of U.S. inventory data. Light, sweet crude for delivery in August, which became the ... Barrons.com Big investors are dumping stocks like it's 2008
Big investors are fleeing stocks. In a note Tuesday, Jill Carey Hall at Bank of America Merrill... Business Insider 5 Stocks Set to Soar on Bullish Earnings
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week. TheStreet.com MU $24.49 -0.57% Darden Restaurants splits company in two
430 of 1,500 properties will make up a new, publicly traded real estate company. USA TODAY DRI $69.39 0.01% 3 Strong Dividend Stocks for Income in Retirement
I like the Golden Arches, a REIT, and a company that has increased its dividend every year for 42 years. Take a look. Kiplinger Buckingham Palace needs repairs; queen may have to leave
LONDON (AP) — Queen Elizabeth II may have to move out of Buckingham Palace during much-needed renovations to the residence, which has not been substantially redecorated since she took the throne in 1952, royal officials said Wednesday. Associated Press
Press Releases
Catalyst Pharmaceuticals Names Richard J. Daly Interim Chief Commercial Officer Catalyst Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference Catalyst Pharmaceuticals Announces First Quarter 2015 Financial Results and Provides Corporate Update
More Press Release for Catalyst Pharmaceuticals, Inc. What to read next
SNGX hod closed after Phase 3 Study news.nice buys( 9 times avr. volume).lets see what today brings: SNGX Soligenix Announces Collaboration with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell Lymphomahttp://www.soligenix.com/news.aspx?titleId=487
Market Data 
Markets 
AI
